IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 814.00
500 μg	5 days	$ 3,250.00
1 mg	5 days	$ 5,440.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 814.00

500 μg

5 days

$ 3,250.00

1 mg

5 days

$ 5,440.00

Description

Species	Cynomolgus
Expression System	HEK293
Tag	C-His
Accession Number	A0A2K5UDJ4
Synonyms	Igifbp, Interleukin-18-binding protein, IL-18BP
Construction	Recombinant Biotinylated Cynomolgus IL-18BP Protein (Primary Amine Labeling) is expressed from HEK293 with His tag at the C-Terminus. It contains Thr28-Pro207.[Accession \|A0A2K5UDJ4]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 21.14 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in PBS (pH 7.4).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.